Solid Tumor Testing Market Report 2026

Solid Tumor Testing Market Overview

• Solid Tumor Testing market size has reached to $29.94 billion in 2025 • Expected to grow to $43.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Growing Cancer Prevalence Drives Solid Tumor Testing Market Expansion • Market Trend: Multi-Omics Liquid Biopsy Platforms Transform Solid Tumor Testing Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Solid Tumor Testing Market?

Solid tumor testing refers to the diagnostic and molecular testing conducted on solid tumors, which are masses or growths of abnormal cells that form in various body tissues. Solid tumor testing is used to detect cancer cells or cancer-related DNA in patients' blood with solid tumors, even if the cancer is not yet visible on imaging tests. The main types of solid tumor testing are genetic testing and conventional testing. Genetic testing refers to a medical test that examines an individual's DNA (genetic material) to identify changes or variations in genes, chromosomes, or proteins. These are used in the treatment of various types of cancer, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer. These are used for several applications, including clinical and research, by various end-users, such as hospitals, pharmaceutical and biotechnology companies, contract research organizations, and academic research institutions.

What Is The Solid Tumor Testing Market Growth Forecast?

The solid tumor testing market size is expected to see strong growth in the next few years. It will grow to $43.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to personalized treatment demand, early detection focus, genomic testing expansion, ai-driven diagnostics, oncology research growth. Major trends in the forecast period include growth of liquid biopsy testing, adoption of next-generation sequencing, expansion of companion diagnostics, AI-based pathology integration, increased screening programs.

Global Solid Tumor Testing Market Segmentation

1) By Type: Genetic Testing, Conventional Testing 2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer 3) By Application: Clinical, Research 4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions Subsegments: 1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH) 2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

What Is The Driver Of The Solid Tumor Testing Market?

An increase in the prevalence of cancer is expected to propel the growth of the solid tumor testing market going forward. Cancer is a condition marked by the body's aberrant cells growing and spreading out of control. These abnormal cells, known as cancer cells, can invade nearby tissues and organs and, in some cases, spread to other parts of the body through the bloodstream or lymphatic system. Most adult cancers are solid tumors, which is about 90%. Solid tumor testing is used to detect cancer cells in the blood of patients with solid tumors, even if the cancer is not yet visible on imaging tests. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, In 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing prevalence of cancer is driving the growth of the solid tumor testing industry.

Key Players In The Global Solid Tumor Testing Market

Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

Global Solid Tumor Testing Market Trends and Insights

Major companies operating in the solid tumor testing market are focusing on developing innovations such as, liquid biopsy platform for solid tumor testing. Liquid biopsy platform encompassing various technologies and systems used to analyze body fluids, typically blood, for cancer-related biomarkers. For instance, in January 2023, PrognomiQ a US-based healthcare company launched multi-omics liquid biopsy platform. PrognomiQ's next phase of product development has begun with the initiation of a 15,000-subject prospective clinical program, which has enrolled its first patient. This initiative was spurred by the potential of multi-omics markers to distinguish between cancer and controls.

What Are Latest Mergers And Acquisitions In The Solid Tumor Testing Market?

In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology Inc. for $450 million. Through this acquisition, Quest Diagnostics aims to expand access to liquid biopsy technology and increase market share in cancer diagnostics through enhanced research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company that develops solid tumor testing technology to improve outcomes for patients with cancer.

Regional Outlook

North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Solid Tumor Testing Market?

The solid tumor testing market consists of revenues earned by entities by providing molecular profiling, next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), and biomarker testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Solid Tumor Testing Market Report 2026?

The solid tumor testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.